Literature DB >> 14642967

Animal behavior models of the mechanisms underlying antipsychotic atypicality.

Mark A Geyer1, Bart Ellenbroek.   

Abstract

This review describes the animal behavior models that provide insight into the mechanisms underlying the critical differences between the actions of typical vs. atypical antipsychotic drugs. Although many of these models are capable of differentiating between antipsychotic and other psychotropic drugs, only a few seem to be able to differentiate between typical and atypical antipsychotics, such as the paw test and the phencyclidine (PCP)-induced disruption of prepulse inhibition (PPI) of startle in rats. Moreover, there is an urgent need for animal models focusing more on the negative and the cognitive symptoms. Hence, improved animal models are crucial for developing better treatments for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642967     DOI: 10.1016/j.pnpbp.2003.09.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  81 in total

1.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

2.  HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Authors:  Alan P Kozikowski; Sung Jin Cho; Niels H Jensen; John A Allen; Andreas M Svennebring; Bryan L Roth
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

3.  Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.

Authors:  S Suratman; K Leach; Pm Sexton; Cc Felder; Re Loiacono; A Christopoulos
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 4.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

Review 5.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 6.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.

Authors:  José L Moreno; Mitsumasa Kurita; Terrell Holloway; Javier López; Richard Cadagan; Luis Martínez-Sobrido; Adolfo García-Sastre; Javier González-Maeso
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

8.  PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.

Authors:  Atheir I Abbas; Prem N Yadav; Wei-Dong Yao; Margaret I Arbuckle; Seth G N Grant; Marc G Caron; Bryan L Roth
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 9.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

10.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Authors:  Lei Wen; Yi-Sheng Lu; Xin-Hong Zhu; Xiao-Ming Li; Ran-Sook Woo; Yong-Jun Chen; Dong-Min Yin; Cary Lai; Alvin V Terry; Almira Vazdarjanova; Wen-Cheng Xiong; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.